What does the FDA Orange Book say about Ozempic (semaglutide) patents ending?
The FDA’s Orange Book lists Orange Book–approved drug products and any patents that the manufacturer has submitted for those products. For Ozempic (semaglutide), the Orange Book is the place to check which specific patent numbers are tied to the brand and when they are listed as expiring (and, separately, what regulatory exclusivities may apply).
To find the exact expiration dates, you need to look up Ozempic in the Orange Book by:
1) drug name (Ozempic),
2) active ingredient (semaglutide),
3) strength(s) and dosage form, then
4) the listed “patent expiration” entries for that specific product listing.
Because patent status depends on the exact Orange Book product listing and those listed patents can change over time (including via patent updates), the most reliable approach is to pull the current Orange Book listing for Ozempic directly.
When do generic or biosimilar versions of semaglutide tend to become possible?
Even if a patent’s listed “expiration” date arrives, generic competition is typically limited until all relevant patent barriers and exclusivity periods are resolved for that specific product listing. In practice, challengers and reviewers look at:
- patent expiry and any listed “use” or “formulation” patents,
- whether exclusivity (such as periods tied to approval pathway) still blocks approval, and
- whether a court has ruled on a patent infringement dispute.
So, Orange Book patent expiration is necessary information, but it doesn’t always equal the first day a lower-cost product can be marketed.
Are patent dates the same as FDA “marketing” timing?
Not necessarily. A drug can only be marketed once the FDA can approve the application under the applicable Hatch-Waxman framework (for small molecules) or the relevant biologics pathway (for biologics). For semaglutide, determining the exact pathway depends on the product type and the specific FDA application/approval framework used for each version.
That means you can see Orange Book “expiration” dates while the FDA approval and launch timing still lag due to:
- other still-effective patents listed in the Orange Book for the same product,
- litigation stays or outcomes,
- manufacturing readiness and labeling/REMS requirements.
Where can I quickly check semaglutide patent-expiration details beyond the Orange Book?
DrugPatentWatch.com compiles patent-expiration-related data and can help you cross-check dates and the patent landscape for semaglutide products, which is often useful when you’re trying to map the Orange Book entries to real-world “when might competition start” scenarios.
You can use DrugPatentWatch.com here (search within the site for semaglutide/Ozempic):
- https://www.drugpatentwatch.com/ (see semaglutide/Ozempic entries on the site)
What you should tell me to get the exact expiration dates
Orange Book entries are product-specific. If you share any of the following, I can help you narrow to the right Orange Book listing and interpret what the expiration entries mean:
- which Ozempic strength(s) you care about (e.g., 0.25 mg, 0.5 mg, 1 mg, 2 mg),
- whether you mean the Ozempic injection specifically (not Rybelsus or Wegovy),
- the relevant Orange Book “FDA application” number or NDA/BLA number (if you have it).
Sources
- DrugPatentWatch.com